90 results about "STD - Sexually transmitted disease" patented technology

The invention relates to methods and products for preventing and / or treating sexually transmitted diseases. A nucleic acid and optionally an anti-STD agent, a birth control agent and / or a birth control device are administered, optionally in the context of a sustained release device to a subject to prevent or treat STD.

The nanometer silver spray for women consists of distilled water, nanometer silver powder, foaming agent, foaming assistant and propellant, and is prepared through dispersing nanometer silver powder into distilled water, adding foaming agent and foaming assistant, filling, and adding propellant. The present invention applies the medicine deeply and makes the medicine foam without flow to maintain long time, and this can prolong the medicine retaining time in the disease focus part to reach high curative effect. The present invention is suitable for use in preventing and treating bacterial, fungal and trichomonad diseases.

The object of the invention is a multiple-channel test devise based on immunodiffusion and immunochromatography, which enables the simultaneous or parallel determination of several analytes. In the test devise, it is possible to group together different combinations of markers recognizing allergens, myocardial infarction markers, venereal disease analytes, blood screening analytes, respiratory infection producing agents, IgG, IgA and IgM antibodies, other infectious disease producing agents as well as various cancer markers. The multiple-channel test devise comprises a porous carrier material on which a channel network has been formed by etching the carrier material by laser to form a shaped figure that contains several channels. In the channels, various specific binding reagents have been immobilized, which enable the diagnoses of a target illness and / or syndrome. The sample application point is optionally provided with a filter and optionally contains a label mobilizable by the analyzable sample and a specific binding reagent. Also the method for the production of the test device and its use are disclosed in the invention.

The drug action mechanisms and core techniques of the present invention are summarized in figure 1. Specifically, the invention provides malignant denatured proteins, such as mutant Huntingtin proteinor alpha-synuclein, stick together to grow into oligomer aggregates (1, 2), fibrillar aggregates (3), and ultimately inclusion bodies (4). Young neuronal cells produce a large quantity of Nt-Arg through N-terminal arginylation (5) of endoplasmic reticulum chaperones, such as BiP, and thereafter, arginylated BiP (R-BiP) comes into the cytoplasm and binds with denatured proteins (6). Nt-Arg of R-BiP, as a ligand, binds with the ZZ domain of p62 (7) to induce the structural activation of p62 (8) while the ordinarily closed inactive form of p62 is changed with an open form thereof, and thus PB1 and LC3-binding domains are exposed. On the basis of oligomerization (9) by the PB1 domain, p62 binds with the denatured protein aggregates to be concentrated to autophagically degradable aggregates, that is, p62 bodies (10). Thereafter, p62 completes autophagy targeting (11) and lysosomal proteolysis through binding with LC3 protruding on the autophagosomal membranes. In young neuronal cells, theautophagic proteolysis occurring through steps 5-11 is strong, and thus the cytotoxic protein aggregates (1-5) do not accumulate, but in aged neuronal cells, the autophagic proteolysis occurring through steps 5-11 is weakened, and thus the protein aggregates (1-5) accumulate, resulting in a vicious cycle. The present invention attempts to effectively remove Huntingtin and alpha-synuclein protein aggregates and the like by artificially activating p62 using low-mass ligands of the p62 ZZ domain (12, 13). Specifically, p62 binding the ligands through step 12 promotes p62-R-BiP-denatured protein oligomerization (9) and autophagy aggregate formation (10). In addition, the ligand-62 conjugates step 13 act as autophagy activators (14), to promote LC3 synthesis, the conversion of LC3-I into LC3-II, and the like, thereby promoting the formation of autophagosomes (15).

The present invention relates to compositions and methods for treating diseases and / or disorders associated with protein aggregates. By expressing a chimeric antigen receptor (CAR) in a monocyte, macrophage or dendritic cell, the modified cell is recruited or applied to the tissue microenvironment where it acts as a potent immune effector by infiltrating the tissue and eliminating, reducing, inhibiting or preventing protein aggregation. Other aspects of this invention include methods and pharmaceutical compositions comprising the CAR modified monocyte, macrophage or dendritic cell for treatinga condition, such as a neurodegenerative disease / disorder, an inflammatory disease / disorder, a cardiovascular disease / disorder, a fibrotic disease / disorder and amyloidosis.

The invention relates to application of a dencichine medicament, in particular to the application of a small dose of dencichine in preparation of a medicament for treating chronic neurologic diseases. A cytological method is used by researchers of the experiment, so that the condition that a small dose of dencichine can achieve a protection effect on neurogenic cell damages caused by a chronic anoxic effect is proved and a protection effect of a small dose of dencichine on the chronic neurologic diseases is prompted by a cellular morphology observation method, a cellular staining method and other methods by establishing a cellular chronic anoxic model and the like.

The present invention relates to 4-substituted phenylamidine derivatives of the general formula (I), wherein R5-R6, ArA4, D, G, B, Q and an integer m have the meanings as defined in the description. The invention further relates to methods for their preparation and use of said compounds for controlling undesired phytopathogenic microorganisms, and agents for said purpose, comprising said phenylamine derivatives. This invention further relates to a method for controlling undesired phytopathogenic microorganisms by application of said 4-substituted phenylamidine derivatives of general formula (I) to such undesired microorganisms and / or to their habitat, according to the invention.

Compositions and methods for manufacturing induced immune regulatory cells comprising induced myeloid suppressive cells including MDSCs (myeloid-derived suppressor cells), dendritic cells, macrophages, and subpopulations thereof are provided. Also provided are methods and compositions for further modifying and modulating the induced immune regulatory cells to achieve enhanced therapeutic potentialin treating autoimmune disorders, hematological malignancies, solid tumors, viral infections, neurodegenerative disorders, inflammatory conditions, or GvHD.

The invention relates to a method of screening for compounds with anti-amyloid properties. The method of screening for compounds which have the ability to dissociate or prevent high-affinity complexes between ss-amyloid peptides and nicotinic acetylcholine receptors of human cortex tissues makes it possible to rapidly identify compounds for use in the curative and / or preventive treatment of neurodegenerative diseases and of Alzheimer's disease in particular.

The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted,4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and / or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.

The invention discloses a pyridopyrimidine compound and application thereof, and belongs to the technical field of biological medicine. The pyridopyrimidine compound disclosed by the invention is a novel compound capable of being used as a PI3K delta inhibitor, and the determination on the activity of PI3K delta kinase and the selective activity of PI3K delta kinase proves that the compound disclosed by the invention has an obvious inhibiting effect on the activity of PI3K delta kinase and has an obvious selective effect on the activity of PI3K delta. In-vitro cell proliferation determination of a leukemia cell line shows that the compound disclosed by the invention has different inhibition effects on leukemia cells. The compounds disclosed by the invention, or pharmaceutically acceptable salts, deuterated compounds, hydrates, solvates, chemically protected prodrugs or combinations thereof, can be used as PI3K delta inhibitors, and play a role in treating and / or preventing inflammatory diseases or tumors.

The present invention relates to the compound (2R,2′R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate) of formula (I), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.